Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim Immunotech, Algernon, Aprea, Gannex, Inovio, Lysogene, Novavax, Taiwan Liposome.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: BMS, Dynavax, Evaxion, Macrogenics, Modag, Oramed, Palvella, Rakuten, Revive, Serum Institute of India, Spectrum, Supernus.

The challenging mucositis space chalked up another failure in dusquetide, the innate defense regulator from Soligenix Inc., which fell short in a pivotal, phase III study that enrolled 268 patients to test the small-molecule peptide. “We sort of thought so,” Dawson James analyst Jason Kolbert in a Dec. 22 report, with a neutral rating and no price target.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Acticor, Amgen, Amo, Apogenix, Ascentage, Astellas, Astrazeneca, Biocryst, Bone, Cardiol, Chemocentryx, Curevac, Fibrogen, Gannex, GW, Kiniksa, Maat, Mapi, Mitsubishi Tanabe, Molecular Templates, Oncopeptides, Ose, Redhill, Rhythm, Soligenix, Synthetic Biologics, Tonix, UItimovacs, Vifor, Vicore.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annexon, Athersys, Atyr, Azura, Biocryst, Bioeclipse, Biomarin, Clovis, Enlivex, Exelixis, Immunitybio, Inotrem, Mustang, Neurana, Oric, Regenacy, Roche, Sellas, Sirnaomics.

In the second half of November, Black Diamond Therapeutics Inc. gained attention from Wall Street by nominating BDTX-1535 as the firm’s development candidate for glioblastoma multiforme (GBM) and kicked off IND-enabling studies.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Bavarian Nordic, Boehringer Ingelheim, Brainstorm Cell, Brii, Eusa, Glaxosmithkline, Medincell, Ology Bioservices, Prilenia, Recardio, Regeneron,Taiwan Liposome, Vir.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Adial, Albireo, Aldeyra, Algernon, Ampio, Biocardia, Calcimedica, Cytodyn, Eusa, Evofem, Galmed, GSK, Humanigen, Immunicum, Metacrine, Molecular Partners, Nextcure, Otonomy, Revance, Vasomune.

A top-line Alzheimer's trial readout, once expected to catalyze value for the Vtv Therapeutics Inc. candidate azeliragon this year, instead hurried a 22.6% decline in company shares (NASDAQ:VTVT) to $2.30 after the phase II study found the drug yet again failed to deliver a statistically significant difference in cognitive decline vs. a placebo in people with mild probable Alzheimer’s disease (AD) and type 2 diabetes (T2D).